<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493402</url>
  </required_header>
  <id_info>
    <org_study_id>hcc-001</org_study_id>
    <nct_id>NCT00493402</nct_id>
  </id_info>
  <brief_title>Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma</brief_title>
  <acronym>TACEforHCC</acronym>
  <official_title>The Efficacy, Safety, and Patient Reported Outcomes of Different Regimens of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 458 Hospital of Chinese PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaiping Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy, safety, and patient reported outcomes
      (PRO) of different regimens of transarterial chemoembolization (TACE) in patients with
      hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transarterial chemoembolization (TACE) has been recommended as first line non-curative
      therapy for non-surgical patients with large/multifocal HCC who do not have vascular invasion
      or extrahepatic spread. There has not been any standardized protocol in the choice of
      chemotherapeutic agents, dosage, dilution, rate of injection, and time interval between
      treatments. Similarly, there is no agreement on the choice of embolizing agents, degree of
      embolization, and whether the chemotherapeutic agent should be given together, or before the
      embolizing agent.

      Comparison(s): In patients with HCC who underwent TACE therapy, stratified by whether they
      have vascular invasion and tumor size, we compare efficacy, safety, and patient reported
      outcomes (PRO) of different regimens of TACE.

      Regimen 1: lipiodol combined chemotherapy with embolization

      Regimen 2: lipiodol combined chemotherapy without embolization

      Regimen 3: lipiodol single agent chemotherapy with embolization
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>combined chemotherapy with embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, with particle embolization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combined chemotherapy without embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, without particle embolization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single agent chemotherapy with embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial chemoembolization (TACE)</intervention_name>
    <description>drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.</description>
    <arm_group_label>combined chemotherapy with embolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial chemoembolization (TACE)</intervention_name>
    <description>drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.</description>
    <arm_group_label>combined chemotherapy without embolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial chemoembolization (TACE)</intervention_name>
    <description>Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.</description>
    <arm_group_label>single agent chemotherapy with embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with minimal height of 150cm and minimal weight of 50 KG

          -  Histological confirmed HCC

          -  with no previous treatment

          -  With unresectable tumor

          -  With solitary or multiple intrahepatic tumor, the diameter of the largest one must
             larger than 7cm.

          -  No significant baseline liver dysfunction. Cirrhotic status of Child-Pugh class A only

          -  No significant renal impairment (creatinine clearance &lt; 30 mL/minute)

          -  The following laboratory parameters:

               -  Platelet count ≥ 60,000/µL

               -  Hemoglobin ≥ 8.5 g/dL

               -  Total bilirubin ≤ 1.5 mg/dL

               -  ASL and AST ≤ 5 x upper limit of normal

               -  Serum albumin ≥ 35 g/L

               -  Serum creatinine ≤ 1.5 x upper limit of normal

               -  INR ≤ 1.5 or a Pt/PTT within normal limits

               -  Absolute neutrophil count (ANC) &gt; 1,500/mm3

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Avascular tumor

          -  Main portal vein obstruction without cavernous transformation

          -  Evidence of hepatic decompensation including esophageal or gastric variceal bleeding
             or hepatic encephalopathy

          -  Obstructive jaundice

          -  Severe underlying cardiac or renal diseases

          -  Known or suspected allergy to the investigational agent or any agent given in
             association with this trial

          -  Pregnant or breast-feeding patients.

          -  History of organ allograft

          -  Active clinically serious infections

          -  Any condition that is unstable or which could jeopardize the safety of the patient and
             his/her compliance in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Qing Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center, Sun Yat-set University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36.</citation>
    <PMID>16250051</PMID>
  </reference>
  <reference>
    <citation>BREEDIS C, YOUNG G. The blood supply of neoplasms in the liver. Am J Pathol. 1954 Sep-Oct;30(5):969-77.</citation>
    <PMID>13197542</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003 Feb;37(2):429-42. Review.</citation>
    <PMID>12540794</PMID>
  </reference>
  <reference>
    <citation>Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, Araki Y, Nishimura Y. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000 Dec;23(6):564-8.</citation>
    <PMID>11202797</PMID>
  </reference>
  <reference>
    <citation>Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 2006 Jan;202(1):155-68. Epub 2005 Oct 19. Review.</citation>
    <PMID>16377509</PMID>
  </reference>
  <reference>
    <citation>Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1535-47. Review.</citation>
    <PMID>16696801</PMID>
  </reference>
  <reference>
    <citation>Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988 Aug 1;62(3):479-83.</citation>
    <PMID>2839280</PMID>
  </reference>
  <reference>
    <citation>Hong K, Georgiades CS, Geschwind JF. Technology insight: Image-guided therapies for hepatocellular carcinoma--intra-arterial and ablative techniques. Nat Clin Pract Oncol. 2006 Jun;3(6):315-24. Review.</citation>
    <PMID>16757969</PMID>
  </reference>
  <reference>
    <citation>Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol. 2001 May-Jun;32(5):383-9. Review.</citation>
    <PMID>11319307</PMID>
  </reference>
  <reference>
    <citation>Kajanti M, Pyrhönen S, Mäntylä M, Rissanen P. Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol. 1992 Feb;15(1):37-40.</citation>
    <PMID>1312770</PMID>
  </reference>
  <reference>
    <citation>Heresbach D, Raoul JL, Bentue-Ferrer D, Bretagne JF, Van den Driessche J, Gastard J. [Chemotherapy combined with Lipiodol. In vitro study of the kinetics of release of adriamycin]. Gastroenterol Clin Biol. 1989 Oct;13(10):775-8. French.</citation>
    <PMID>2556315</PMID>
  </reference>
  <reference>
    <citation>Higashi S, Shimizu M, Nakashima T, Iwata K, Uchiyama F, Tateno S, Tamura S, Setoguchi T. Arterial-injection chemotherapy for hepatocellular carcinoma using monodispersed poppy-seed oil microdroplets containing fine aqueous vesicles of epirubicin. Initial medical application of a membrane-emulsification technique. Cancer. 1995 Mar 15;75(6):1245-54.</citation>
    <PMID>7882276</PMID>
  </reference>
  <reference>
    <citation>Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, Messner M, Gosselin M. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer. 1992 Aug 1;70(3):585-90.</citation>
    <PMID>1320447</PMID>
  </reference>
  <reference>
    <citation>Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, Fujita M, Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989 Oct;97(4):965-71.</citation>
    <PMID>2550311</PMID>
  </reference>
  <reference>
    <citation>Nakao N, Uchida H, Kamino K, Nishimura Y, Ohishi H, Takayasu Y, Miura K. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis. Cardiovasc Intervent Radiol. 1994 Mar-Apr;17(2):76-80.</citation>
    <PMID>8013027</PMID>
  </reference>
  <reference>
    <citation>Nakao N, Uchida H, Kamino K, Nishimura Y, Ohishi H, Takayasu Y, Nakamura H, Kuroda C, Fujita M, Yoshioka H, et al. Effectiveness of Lipiodol in transcatheter arterial embolization of hepatocellular carcinoma. Cancer Chemother Pharmacol. 1992;31 Suppl:S72-6.</citation>
    <PMID>1333913</PMID>
  </reference>
  <reference>
    <citation>Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987 May;163(2):345-51.</citation>
    <PMID>3031724</PMID>
  </reference>
  <reference>
    <citation>Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989 Mar;170(3 Pt 1):783-6.</citation>
    <PMID>2536946</PMID>
  </reference>
  <reference>
    <citation>Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer. 1990 Nov 1;66(9):1897-903.</citation>
    <PMID>2171752</PMID>
  </reference>
  <reference>
    <citation>Egawa H, Maki A, Mori K, Yamamoto Y, Mitsuhashi S, Bannai K, Asano K, Ozawa K. Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol. 1990 Jun;44(2):109-14.</citation>
    <PMID>2162452</PMID>
  </reference>
  <reference>
    <citation>Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem. 2001 Nov 16;276(46):43407-12. Epub 2001 Sep 13.</citation>
    <PMID>11557773</PMID>
  </reference>
  <reference>
    <citation>Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S211-21. Review.</citation>
    <PMID>12354839</PMID>
  </reference>
  <reference>
    <citation>Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002 Jul;224(1):47-54. Review.</citation>
    <PMID>12091661</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.</citation>
    <PMID>12049862</PMID>
  </reference>
  <reference>
    <citation>Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71.</citation>
    <PMID>11981766</PMID>
  </reference>
  <reference>
    <citation>Homma H, Mezawa S, Doi T, Miyanishi K, Takada K, Kukitsu T, Oku T, Masuko E, Nojiri S, Niitsu Y. A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV). Hepatogastroenterology. 2004 Jul-Aug;51(58):1135-9.</citation>
    <PMID>15239261</PMID>
  </reference>
  <reference>
    <citation>Stuart K. Chemoembolization in the management of liver tumors. Oncologist. 2003;8(5):425-37. Review.</citation>
    <PMID>14530495</PMID>
  </reference>
  <reference>
    <citation>Geschwind JF, Ramsey DE, Cleffken B, van der Wal BC, Kobeiter H, Juluru K, Hartnell GG, Choti MA. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol. 2003 Mar-Apr;26(2):111-7. Epub 2003 Mar 6.</citation>
    <PMID>12616414</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2007</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>administration &amp; dosage</keyword>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Chemoembolization, Therapeutic</keyword>
  <keyword>Humans</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

